• COVID-19
  • Allergies and Infant Formula
  • Pharmacology
  • Telemedicine
  • Drug Pipeline News
  • Influenza
  • Allergy, Immunology, and ENT
  • Autism
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious disease
  • Nutrition
  • Neurology
  • Obstetrics-Gynecology & Women's Health
  • Developmental/Behavioral Disorders
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Diabetes
  • Mental Health
  • Oncology
  • Psychiatry
  • Animal Allergies
  • Alcohol Abuse
  • Rheumatoid Arthritis
  • Sexual Health
  • Pain

Tinea Capitis

Article

In this infant, microscopic examination of a potassium hydroxide preparation of scalp scrapings revealed Trichophyton tonsurans, which is the most common causative organism in North America.

FigureThis circular lesion on the scalp of a 3-week-old infant is tinea capitis-a rare disorder in a neonate. A 2003 epidemiological survey revealed a striking increase in tinea capitis among African American children. The study showed that the carrier rate for scalp fungus with cultures that are positive for dermatophytes was up to 13% among African American children in elementary school.

1

In this infant, microscopic examination of a potassium hydroxide preparation of scalp scrapings revealed Trichophyton tonsurans, which is the most common causative organism in North America.

Treatment of tinea capitis is variable. Most medications are not FDA-approved, and few published trials discuss treatment for very young children. Most experts use high-dose oral griseofulvin (20 to 25 mg/kg/d for 6 to 8 weeks) as first-line therapy, because lower dosages have been proved to have higher treatment failures. Several other equally effective therapies, such as terbinafine, itraconazole, and fluconazole (at 3 to 6 mg/kg/d for 2 to 4 weeks), have been used outside the United States and off-label; however, these treatments cost significantly more.2 There is one report of a 16-day-old infant who did well after treatment with topical bifonazole 1%.3 Selenium sulfide shampoo can be used as adjunctive therapy.

In this infant, treatment with griseofulvin (20 mg/d for 6 weeks) led to complete resolution of the lesion with no side effects.

References:

  • Ghannoum M, Isham N, Hajjeh R, et al. Tinea capitis in Cleveland: survey of elementary school students. J Am Acad Dermatol. 2003;48:189-193.

  • Roberts BJ, Friedlander SF. Tinea capitis: a treatment update. Pediatr Ann. 2005;34:191-200.

  • Mosseri R, Finkelstein Y, Garty BZ. Topical treatment of tinea capitis in a neonate. Cutis. 2002;69:88-90.
Related Videos
Lawrence Eichenfield, MD
Lawrence Eichenfield, MD | Image credit: KOL provided
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older | Image Credit: bankrx - Image Credit: bankrx - stock.adobe.com.
Related Content
© 2024 MJH Life Sciences

All rights reserved.